Literature DB >> 18074863

Relationship of P-cadherin expression to basal phenotype of breast carcinoma.

Piotr Potemski1, Renata Kusińska, Robert Kubiak, Janusz H Piekarski, Elzbieta Płuciennik, Andrzej K Bednarek, Radzisław Kordek.   

Abstract

BACKGROUND: P-cadherin (P-CD) is a molecule expressed mainly by basal cells involved in cell adhesion. We evaluated expression of P-CD in operable breast carcinomas and its relationship with immunohistochemical markers of the basal-like phenotype and with clinical outcome.
MATERIAL AND METHODS: Expression of P-CD was analyzed by immunohistochemistry in 194 tissue specimens of invasive operable ductal breast cancer.
RESULTS: 112 cases (57.7%) were identified as being P-CD-positive. P-CD-positive tumors usually lacked steroid receptors (p = 0.042), expressed basal type cytokeratins (p = 0.001), and were positive for cyclin E (p = 0.039). In a univariate analysis of cancer-specific survival with a median follow-up period of 58 months, P-CD expression was not associated with prognosis (5-year survival rate for positive vs. negative patients 67.0 vs. 77.0%, log rank p = 0.121).
CONCLUSION: P-CD may be regarded as an additional immunohistochemical marker of basal-like breast carcinomas. However, P-CD expression is not an adverse prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18074863

Source DB:  PubMed          Journal:  Pol J Pathol        ISSN: 1233-9687            Impact factor:   1.072


  2 in total

1.  Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.

Authors:  Sharon A Glynn; Brenda J Boersma; Tiffany H Dorsey; Ming Yi; Harris G Yfantis; Lisa A Ridnour; Damali N Martin; Christopher H Switzer; Robert S Hudson; David A Wink; Dong H Lee; Robert M Stephens; Stefan Ambs
Journal:  J Clin Invest       Date:  2010-10-18       Impact factor: 14.808

2.  Biomarkers for Basal-like Breast Cancer.

Authors:  Jennifer R Choo; Torsten O Nielsen
Journal:  Cancers (Basel)       Date:  2010-05-28       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.